Trial Profile
A single-center study to evaluate the efficacy and safety of radium-223 chloride in patients with metastatic castration resistant prostate cancer and bone metastases in real-world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2016 New trial record